首页>European urology>Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: Data from the tax327 study
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: Data from the tax327 study
作者单位:Sanofi, Malvern, PA, United States[1]Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada[2]Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States[3]Department of Urology, Erasmus University Medical Center, Dr. Molewaterplein 50, Be-331, 3015 GE[4]Department of Medical Oncology, Erasmus University, Medical Center and Erasmus MC Cancer Institute[5]